Ergomed plc (2EM.DE) Comparison with companies in other sectors?

Ergomed plc has a share price of 53.27M. You can analyze Ergomed plc (2EM.DE) competitors across different market sectors through stock heatmaps.

What are 2EM.DE's NET and operating margins?

Ergomed plc (2EM.DE) operating margin is around 0.13, and net profit margin is approximately 0.10 as of the latest reports.

In what way does 2EM.DE's earnings per share (EPS) trend reflect its financial momentum?

Ergomed plc (2EM.DE) EPS is 0.32 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Ergomed plc is 34.38, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Ergomed plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Ergomed plc like P/E which is 68.30, P/B which is 12.07, and PEG which is 0.79. Compare them with sector averages to evaluate if the stock is priced fairly.

Ergomed plc

2EM.DE•XETRA

Healthcare

Biotechnology

€11.00

€0.00(0.00%)

Ergomed plc (2EM.DE) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.32

P/E Ratio

34.38

ROE

0.20%

Net Margin

0.10%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$585.99M

Shares OutstandingTotal number of shares issued

$53.27M

Book Value/ShareNet worth per share

$0.79

Revenue/ShareAnnual revenue per share

$1.35

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.32

Net MarginNet income as percentage of revenue

10.31%

Operating MarginOperating income as percentage of revenue

12.99%

ROEReturn on shareholders' equity

19.71%

ROAReturn on total assets

11.58%

ROCEReturn on capital employed

20.86%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.12

Cash/ShareCash and equivalents per share

$0.18

FCF YieldFree cash flow as percentage of market cap

2.55%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2EM.DEFinancial Ratios Analysis details for 2EM.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2EM.DESector Benchmarking details for 2EM.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Ergomed plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Ergomed plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Ergomed plc's unique business strengths and challenges.

Key Financial Metrics for Ergomed plc

For Ergomed plc, essential financial indicators include EPS 0.32, PE 34.38, and ROE 0.20. These key ratios reveal insights into Ergomed plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Ergomed plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Ergomed plc

Metrics like Net Margin 10.31% and ROA 11.58% shed light on how well Ergomed plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Ergomed plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Ergomed plc

Using ratios such as P/B Ratio 12.07 and PEG Ratio 0.79, investors can assess whether Ergomed plc is appropriately valued based on its financials and growth potential. These figures, combined with Ergomed plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Ergomed plc

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $0.12, provide a snapshot of Ergomed plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Ergomed plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Ergomed plc

Investing in Ergomed plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Ergomed plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;